ATE312934T1 - Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit - Google Patents

Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit

Info

Publication number
ATE312934T1
ATE312934T1 AT96919292T AT96919292T ATE312934T1 AT E312934 T1 ATE312934 T1 AT E312934T1 AT 96919292 T AT96919292 T AT 96919292T AT 96919292 T AT96919292 T AT 96919292T AT E312934 T1 ATE312934 T1 AT E312934T1
Authority
AT
Austria
Prior art keywords
genes
permissive
environment
environmentally
microorganisms
Prior art date
Application number
AT96919292T
Other languages
English (en)
Inventor
Roy Curtiss Iii
Steven A Tinge
Original Assignee
Univ Washington
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Avant Immunotherapeutics Inc filed Critical Univ Washington
Application granted granted Critical
Publication of ATE312934T1 publication Critical patent/ATE312934T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96919292T 1995-06-07 1996-06-07 Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit ATE312934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47378995A 1995-06-07 1995-06-07
PCT/US1996/009774 WO1996040947A1 (en) 1995-06-07 1996-06-07 Recombinant bacterial system with environmentally limited viability

Publications (1)

Publication Number Publication Date
ATE312934T1 true ATE312934T1 (de) 2005-12-15

Family

ID=23880978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919292T ATE312934T1 (de) 1995-06-07 1996-06-07 Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit

Country Status (8)

Country Link
US (3) US6610529B1 (de)
EP (1) EP0832255B1 (de)
JP (1) JPH11507532A (de)
AT (1) ATE312934T1 (de)
AU (1) AU711618B2 (de)
CA (1) CA2222761A1 (de)
DE (1) DE69635579D1 (de)
WO (1) WO1996040947A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312934T1 (de) * 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
JP3549210B2 (ja) * 1996-03-13 2004-08-04 タカラバイオ株式会社 プラスミド
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6537558B2 (en) 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
EP1192242B1 (de) * 1999-06-25 2010-05-05 Wyeth Holdings Corporation Herstellung der lipid-modifizierten form des peptidoglykan-assoziierten lipoproteins aus gram-negativen bakterien
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
GB0012233D0 (en) * 2000-05-19 2000-07-12 Devgen Nv Vector constructs
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
US9061075B2 (en) 2005-12-14 2015-06-23 The Invention Science Fund I, Llc Bone delivery device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US7855062B2 (en) 2005-12-14 2010-12-21 The Invention Science Fund I, Llc Bone cell delivery device
US8900865B2 (en) 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
US8852916B2 (en) * 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8354258B2 (en) 2005-12-14 2013-01-15 The Invention Science Fund I, Llc Diatom device
US9005944B2 (en) 2005-12-14 2015-04-14 The Invention Science Fund I, Llc Bone cell delivery device
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20080124355A1 (en) * 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
CN101730737B (zh) * 2007-04-24 2016-06-01 赛尔戴克斯治疗公司 超表达重组霍乱毒素b亚单位的霍乱弧菌显示双重免疫原性
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
US8465755B2 (en) 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
PE20110480A1 (es) * 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
US8551749B2 (en) 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
WO2012003460A2 (en) 2010-07-02 2012-01-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
WO2012054693A1 (en) * 2010-10-22 2012-04-26 Trudeau Institute Uses of yersinia yope peptide, gene, and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
WO2012087483A1 (en) * 2010-11-24 2012-06-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium comprising a toxin/antitoxin system
US20120107888A1 (en) * 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9605267B2 (en) 2012-08-02 2017-03-28 University Of Central Florida Research Foundation, Inc. Compositions and methods for genetic constructs
WO2014145346A2 (en) * 2013-03-15 2014-09-18 Bacterial Robotics, Llc Compositions, systems and methods for protecting genetically modified organisms from unauthorized use or release into the environment
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11766461B2 (en) 2016-04-20 2023-09-26 The Board of Trustees of the Stanford Junior Compositions and methods for nucleic acid expression and protein secretion in Bacteroides
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
EP3864048A1 (de) 2018-10-11 2021-08-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Bakterien, die einzelkettige antikörper gegen toll-ähnliche rezeptoren exprimieren
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
JP7764009B2 (ja) * 2021-03-26 2025-11-05 国立研究開発法人農業・食品産業技術総合研究機構 環境によって制御される生存能を有する細胞
BR112023020563A2 (pt) * 2021-04-05 2023-12-19 Univ Maryland Bactérias modificadas, método, formulação de vacina, e, artigo de manufatura
WO2025240926A1 (en) * 2024-05-17 2025-11-20 University Of Iowa Research Foundation Neisseria gonorrhoeae vaccines and treatments and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968619A (en) * 1976-09-27 1990-11-06 Research Corporation Modified microorganisms and method of preparing and using same
US4190495A (en) * 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4506013A (en) * 1980-10-03 1985-03-19 Eli Lilly And Company Stabilizing and selecting recombinant DNA host cells
US4650761A (en) * 1981-11-27 1987-03-17 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cell
US4436815A (en) * 1981-11-27 1984-03-13 Eli Lilly And Company Method for stabilizing and selecting recombinant DNA containing host cells
US5702916A (en) * 1982-09-16 1997-12-30 Gx Biosystems A/S Biological Containment
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
US5855880A (en) * 1987-06-04 1999-01-05 Washington University Avirulent microbes and uses therefor
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
AU637969B2 (en) 1987-10-07 1993-06-17 Washington University A method of maintaining a desired recombinant gene in a genetic population of cells
US5185431A (en) * 1988-08-31 1993-02-09 Eisai Co., Ltd. Recombinant natural killer cell activator
DE3936408A1 (de) * 1989-11-02 1991-05-08 Merck Patent Gmbh Ueberexpression von proteinen in rekombinanten wirtszellen
IE892893A1 (en) * 1990-03-11 1991-09-25 Charles O Kane Phage-like bacteriocins
AU9094191A (en) * 1990-11-21 1992-06-25 Washington University Recombinant avirulent salmonella antifertility vaccines
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
US5589380A (en) * 1992-06-05 1996-12-31 University Of Maryland At Baltimore Isolated DNA molecule encoding SHET1 of Shigella flexneri 2a and mutant Shigella flexneri 2a
EP0692031B1 (de) * 1993-02-22 2007-04-11 The General Hospital Corporation Heterologe antigene in stämmen zur impfung mit lebendzellen
KR960703172A (ko) * 1993-11-18 1996-06-19 스티븐 제이. 멘토 조건적으로 치사적인 유전자를 활용하기 위한 조성물 및 방법(Compositions and methods for utilizing conditionally lethal genes)
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US5681745A (en) * 1995-05-01 1997-10-28 Trustees Of Boston University Biotin-binding containment systems
ATE312934T1 (de) * 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
EP0942964A2 (de) * 1996-11-22 1999-09-22 Human Genome Sciences, Inc. Nukleinsaeuresequenz von pathogenizitaetsinseln von escherichia coli
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
WO2002096195A1 (en) * 2001-05-31 2002-12-05 Enteromed, Inc. Treatment or replacement therapy using transgenic stem cells delivered to the gut
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters

Also Published As

Publication number Publication date
US6610529B1 (en) 2003-08-26
EP0832255A1 (de) 1998-04-01
WO1996040947A1 (en) 1996-12-19
JPH11507532A (ja) 1999-07-06
US7871604B1 (en) 2011-01-18
EP0832255B1 (de) 2005-12-14
CA2222761A1 (en) 1996-12-19
DE69635579D1 (de) 2006-01-19
US20040208897A1 (en) 2004-10-21
AU6166496A (en) 1996-12-30
AU711618B2 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
DE69635579D1 (de) Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
Moran et al. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection
Duc et al. Bacterial spores as vaccine vehicles
ES2152929T3 (es) Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes.
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
HUP0300793A2 (hu) Szabályozott antigénszállító rendszer (RADS)
PE20030239A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
Gong et al. Rickettsia rickettsii outer membrane protein YbgF induces protective immunity in C3H/HeN mice
EP1117767A4 (de) Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
BR0009663A (pt) Composições de vacinas antibacterianas
Dinter et al. Differentiation of porcine mycoplasma strains
BR0103887C1 (pt) Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
MY129859A (en) Bacterial strains of the bacterium bacillus thuringiensis and uses therefor
Varinrak et al. Cross-protection conferred by immunization with an rOmpH-based intranasal fowl cholera vaccine
Confer et al. Serum antibody responses of cattle vaccinated with partially purified native Pasteurella haemolytica leukotoxin
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
ATE420960T1 (de) Impfstoffe auf der basis von invasiven bakterien
AU1853995A (en) Vaccine compositions
CA2128247A1 (en) Vaccines based on streptokinase
McNeill et al. Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines
Pourreau et al. Modulation of the mitogenic PHA response of carp, Cyprinus carpio L., by extracellular products of Aeromonas salmonicida
Rodriguez‐Monroy et al. Striking activation of NALT and nasal passages lymphocytes induced by intranasal immunization with Cry1Ac protoxin
Blanco et al. Mycobacterium bovis mutant in the virulence factors PhoP, ESAT-6 and CFP-10 persisted in mouse organs after a year post-vaccination
Dougan et al. Live bacterial vaccine for delivering antigens to the mammalian immune system.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties